Jennifer Barrett, Associate Editor

Risperidone (Perseris, Indivior) is the first once-monthly subcutaneous risperidone-containing, long-acting injectable for the treatment of schizophrenia in adults.

Study evaluates doravirine once daily compared with ritonavir-boosted darunavir, each taken in combination with other antiretroviral agents.

Use of Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg) for HIV prevention was associated with a significant decline in new diagnoses across the United States.

Study investigates complementary medicine use in patients with curable cancer types and its impact on survival and adherence to conventional therapy.

Nationwide analysis of Truvada for pre-exposure prophylaxis use finds uptake associated with significant decrease in new HIV infections.

Study examines the relationship between drinking artificially sweetened beverages and colon cancer disease recurrence and death.

Using targeted therapies in patients with gliobastoma who have the mutation may reduce tumor growth and improve survival outcomes.

Researchers estimated whether a hepatitis C vaccine could reduce transmission of the virus among injection drug users, even without providing complete immunity.

Adding acetazolamide to chemotherapy temozolomide for glioblastoma increased sensitivity to treatment and improved survival in animal models.

Study establishes increased risk of all-site cancer for both men and women with diabetes, but the excess risk of cancer is greater for women.

Taking advantage of cost-effective generic medications can improve access to hepatitis B treatment, especially in countries with a high disease burden.

Mapping iron concentration in certain regions of the brain may help predict multiple sclerosis progression risk.

The approval of ivosidenib fills an unmet need for patients with relapsed or refractory acute myeloid leukemia who have an IDH1 genetic mutation.

Survivors of cancer in adolescence and young adulthood may be at higher risk for endocrine diseases, such as thyroid disease, testicular dysfunction, and diabetes.

Gene-editing technology could lead to new targeted therapies and help clinicians catch developing cancers before they metastasize.

New research has associated certain health problems with later diagnosis of multiple sclerosis.

Symtuza (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg) is the first and only complete darunavir-based single tablet regimen (STR) for the treatment of HIV-1 in treatment-naïve and certain virologically suppressed adults.

The investigational treatment could benefit patients with amyotrophic lateral sclerosis whose disease is caused by mutations in the SOD1 gene.

The approval is based on data from 2, phase 3 studies, AMBER and EMERALD, which evaluated the safety and efficacy of Symtuza compared with a control regimen in adults with no prior antiretroviral (ARV) history and in virologically suppressed adults.

Symtuza (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg) offers a new treatment option to adults living with HIV.

Study finds that specialty drug coverage policies are mostly inconsistent across health plans and many treatments have multiple restrictions to access.

Supplementation of the protein in the nerve cells prevented nerve degeneration, muscle atrophy, and paralysis in an amyloid lateral sclerosis mouse model.

Individuals treated for cancer in adolescence or young adulthood may be at higher risk for endocrine diseases, such as thyroid disease, testicular dysfunction, and diabetes.

A new study provides insight into previously unknown details about the capsid that may have implications for the development of new drugs to treat the infection.

Enzalutamide (Xtandi) is the first and only FDA-approved oral medication for both non-metastatic and metastatic castration-resistant prostate cancer.

Officials with the FDA have approved tecovirimat (TPOXX, SIGA), the first drug with an indication for the treatment of smallpox, to boost preparedness in the event of a bioterror attack

Researchers aim to determine whether an annual brain volume loss rate of less than 0.4% is a valid marker to assess treatment response.

With this new indication, enzalutamide is the first and only FDA-approved oral medication for both non-metastatic and metastatic CRPC.

Cognitive impairment is present in up to 70% of patients with multiple sclerosis, but can be difficult to completely evaluate in routine clinical practice.